Answers to Everyday Practice Challenges in Dermatology
Focus on Psoriasis
Clinical Practice Guidelines
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Singh JA, Guyatt G, Ogdie A, et al. Arthritis Care Res. 2018,71(1):2-29.
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
Coates LC, Soriano ER, Corp N, et al. Nat Rev Rheumatol. 2022;18(8):465-479.
Joint American Academy of Dermatology—National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients
Menter A, Cordoro KM, Davis DMR, et al. J Am Acad Dermatol. 2020;82(1):161-201.
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Menter A, Atrober BE, Kaplan DH, et al. J Am Acad Dermatol. 2019;80(4):1029-1072.
Patient and Caregiver Resources
American Academy of Dermatology
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
National Psoriasis Foundation
Suggested Readings
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
Armstrong AW, Gooderham M, Warren R B, et al. J Am Acad Dermatol. 2023;88(1):29-39.
Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a phase 3 double-blind randomized, controlled trial.
Bodemer C, Kaszuba A, Kingo K et al. J Eur Acad Dermatol Venereol, 2021;35(4):938-947.
Cardiovascular risk in patients with psoriasis: JACC review topic of the week.
Garshick, MS, Ward NL, Krueger JG, et al. J Am Coll Cardiol, 2021;77(13):1670-1680.
The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool.
Husni ME, Meyer KH, Cohen DS, et al. J Am Acad Dermatol. 2007; 57(4):581-587.
Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
Paller AS, Seyger MMB, Alejandro Magariños G, et al. Br J Dermatol. 2020;183(2):231-241.
Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council.
Strober B, Ryan C, van de Kerkhof P, et al. J Am Acad Dermatol. 2020; 82(1):117-122.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
Strober B, Thaçi D, Sofen H, et al. J Am Acad Dermatol, 2023;88(1):40-51.
Direct comparison of real-world effectiveness of biologics for psoriasis using absolute and relative Psoriasis Area and Severity Index scores in a prospective multicentre cohort.
Van Muijen ME, Thomas SE, Groenewoud HMM, et al. Acta Derm Venereol, 2022;102:206.
Relevant Resources
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Proactive Diagnosis and Targeted Management
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Evolving Strategies for Diagnosis and Long-Term Management
Consensus and Controversies for Responsible Opioid Prescribing
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Improving Outcomes for Patients with COPD
New Strategies for Insulin Replacement Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Identifying Patients and Tailoring Therapy
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A Focus on Patients With Opioid-Induced Constipation
Consensus and Controversies Across the Spectrum of Patient Presentations
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Pathophysiology to the Management of Moderate-to-Severe Disease
Evolving Best Practices to Optimize Outcomes
New Strategies to Target Remission and Individualize Comprehensive Care
Targeting Immune Dysregulation and Delivering Comprehensive Care
The PCP’s Role in Timely Recognition and Referral
Looking Beyond Barriers to Optimize Therapy
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
Key Issues Impacting OB/GYN Practice
Debates and Discussions About Pustular Disease Subtypes
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Collaborative Care for Better Patient Outcomes
Improving Patient Outcomes Through Shared Clinical Decision Making
Digging Deep on Shared Decision-Making
Mechanistic Insights and Evolving Treatment Options
Clinical Resource Center
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
A PrEP Primer
A Foundation for Managed Care
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Best Practices for Primary Care
New Paths to Chronic Pain Management
What the Pharmacist Needs to Know about PrEP
Unlocking Novel Paths to Patient Care
Pathophysiology, Multimodal Management, and Shared Clinical Decision Making
The Increasing Role of JAK Inhibitors
Preventing COPD Exacerbations to Improve Outcomes
A Whole Patient Case Series
Getting on the Fast Track to Identify AxSpA
Establishing Clinical Readiness Through Mentored Learning
A Case-Based Update
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
Reducing LDL-C and a Lifetime of Cardiovascular Risk
Updates, Clinical Scenarios, and Future Directions
A Multidisciplinary Look at Early Diagnosis and Management
Best Practices for Diagnosis and Management
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
Are You Aware of New Blood-Based Multi-Cancer Screening Tools
A Case-Based Update on Pediatric Patients
An Interactive Educational Journey
A Look at the Changing HIV Playing Field
A “How To” Series Spanning Policy to Practice
Test Your Mastery!
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention
Strengthening Your Knowledge of Blood-Based Screening Tools
Bringing HIV Prevention to a New Level
Optimizing HIV Prevention in Primary Care
What You Need to Know About New Blood-Based Screening Tools
Monoclonal Antibodies for the Prevention and Treatment of COVID-19
Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis
Practical Updates on the 2023 GOLD Guidelines
A Phone-a-Friend CME Series – Volume 2
Incorporating New Data and Updated Guidelines Into Daily Practice
Capitalizing on BCMA-Directed Therapies
